Toll Free: 1-888-928-9744

Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Pipeline Review, H1 2016

Published: May 31, 2016 | Pages: 49 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Pipeline Review, H1 2016', provides in depth analysis on Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted pipeline therapeutics. 

The report provides comprehensive information on the Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R)
- The report reviews Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) Overview 6 Therapeutics Development 7 Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Products under Development by Stage of Development 7 Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Products under Development by Therapy Area 8 Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Products under Development by Indication 9 Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Products under Development by Companies 12 Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 17 Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Companies Involved in Therapeutics Development 19 Naia Limited 19 Shire Plc 20 Tasly Pharmaceutical Group Co., Ltd. 21 Zealand Pharma A/S 22 Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Drug Profiles 23 FE-203799 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 GXG-8 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 NB-1002 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 teduglutide (recombinant) - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 ZP-1848 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 ZPGG-23 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 ZPGG-72 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Dormant Projects 35 Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Featured News & Press Releases 36 Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016 36 Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome 36 Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX 37 Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan 37 Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data 38 Jun 17, 2014: Zealand presented new data on GLP-1/GLP-2 novel peptide therapeutics from its preclinical diabetes pipeline at the American Diabetes Association's (ADA) 74th Scientific Sessions 39 Jan 02, 2014: NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome 39 Nov 13, 2013: NPS Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Gattex for Injection 40 Oct 14, 2013: New Data from STEPS 2 Support the Long Term Use of Gattex for Injection in Adult Patients with Short Bowel Syndrome 41 Oct 02, 2013: NPS Pharmaceuticals Reports Gattex STEPS 2 Study to be Presented at American College of Gastroenterology Meeting 42 Jan 30, 2013: New Peer-reviewed Publication Offers Guidance For Integrating Gattex For Injection Into Management Of Short Bowel Syndrome 43 Jan 02, 2013: ThriveRx Receives Limited Distribution Rights To NPS Pharma's Gattex For Treatment Of Short Bowel Syndrome In Adults 45 Dec 27, 2012: Coram Specialty Infusion Services To Provide NPS Pharma's Gattex For Treatment Of Short Bowel Syndrome 45 Dec 21, 2012: NPS Pharma's Gattex Receives FDA Approval For Treatment Of Short Bowel Syndrome 46 Nov 29, 2012: NPS Pharma Announces Publication Of Pivotal Phase III Study Of Gattex In Short Bowel Syndrome-intestinal Failure Patients 47 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 48 Disclaimer 49
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 15 Number of Products by Stage and Route of Administration, H1 2016 16 Number of Products by Stage and Molecule Type, H1 2016 18 Pipeline by Naia Limited, H1 2016 19 Pipeline by Shire Plc, H1 2016 20 Pipeline by Tasly Pharmaceutical Group Co., Ltd., H1 2016 21 Pipeline by Zealand Pharma A/S, H1 2016 22 Dormant Projects, H1 2016 35


List of Figures
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Actions, H1 2016 15 Number of Products by Stage and Routes of Administration, H1 2016 16 Number of Products by Molecule Types, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 17

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

U.S hairbrush market is estimated to exceed USD 1.2 billion by 2022, as per a new research report by Radiant Insights, Inc. Rising population along with ascending disposable income is expected to drive industry demand. Significant rise in disposable

Read More...

Global Bio polyethylene terephthalate (PET) market size is likely to be valued at USD 12.6 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing preference of biopolymers in numerous applications coupled with favorable gover

Read More...

Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing ap

Read More...

Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growi

Read More...

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify